<DOC>
	<DOC>NCT02447796</DOC>
	<brief_summary>The investigators designed a prospective randomized study to compare the conventionally used sedative drug propofol with a latest alternative dexmedetomidine (DEX), in patients with end-stage renal disease undergoing arteriovenous fistula (AVF) surgery.</brief_summary>
	<brief_title>Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery</brief_title>
	<detailed_description />
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Hypnotics and Sedatives</mesh_term>
	<criteria>Inclusion criteria were patients undergoing arteriovenous fistula (AVF) surgery aged between 2070 with end stage renal failure on dialysis treatment. Exclusion criteria were decompensated respiratory or heart failure, liver failure, obesity (body mass index&gt;30), severe obstructive sleep apnea, need for additional different drugs for sedation, chronic use of alcohol, opioids or other sedative drugs,mental disorders, cognitive disorders, language problems and history of allergy to any medications used in this study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>(AVF)</keyword>
	<keyword>surgery</keyword>
</DOC>